SCHEMBL3602570

SCHEMBL3602570

N=C(N)Nc1nc(-c2cccc(O)c2)cs1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.67
VCP P55072 2/20 0.65
ALOX5 P09917 3/20 0.58
HSD17B1 P14061 1/20 0.56
HSD17B2 P37059 1/20 0.56
ATP4A P20648 2/20 0.56
ATP4B P51164 2/20 0.56
SIRT5 Q9NXA8 1/20 0.52
CYP19A1 P11511 1/20 0.50
ROCK1 Q13464 2/20 0.49
PLG P00747 1/20 0.49
PLAU P00749 1/20 0.49
PLAT P00750 1/20 0.49
PRSS1 P07477 1/20 0.49
PRKACA P17612 1/20 0.49
CFTR P13569 2/20 0.48
IDO1 P14902 1/20 0.48
GUSB P08236 1/20 0.48
AMY1A P0DUB6 1/20 0.48
ROCK2 O75116 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393684 0.86 HDAC3 (0.59) ABL1VCPALOX5ROCK1ROCK2
SCHEMBL3615155 0.86 ALOX5 (0.51) ABL1VCPALOX5ATP4AATP4B
SCHEMBL11239265 0.86 MAPT (0.57) ABL1VCPALOX5NPC1ALDH1A1
SCHEMBL11090239 0.86 MAPT (0.51) ABL1VCPALOX5PRSS1NPC1
Hydrochloric Acid SCHEMBL11254127 0.85 HDAC3 (0.60) ABL1VCPALOX5ATP4AATP4B
SCHEMBL3606891 0.85 ABL1 (0.68) ABL1ATP4AATP4BCFTRALDH1A1
SCHEMBL3604035 0.85 ATP4A (0.56) ABL1VCPATP4AATP4BSIRT5
Bromide SCHEMBL7141567 0.85 HDAC3 (0.58) ABL1VCPALOX5ATP4AATP4B
SCHEMBL30660070 0.85 MEN1 (0.61) ABL1VCPGUSBNPC1ALDH1A1
SCHEMBL28902768 0.85 MEN1 (0.61) ABL1VCPGUSBNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 ABL1 4507/4885VCP 1390/4885ALOX5 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.